Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Inc., GlaxoSmithKline, Bristol-Myers, Eli Lilly and Pfizer

http://www.zacks.com/
CHICAGO--(Business Wire)--
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day
the Zacks Equity Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the blog include:
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), GlaxoSmithKline (NYSE: GSK),
Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from
the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Monday`s Analyst Blog:

Isis Inks Deal with Glaxo

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) recently inked a major deal with
GlaxoSmithKline (NYSE: GSK) under which Isis ` antisense drug discovery platform
will be used for the development of new treatments for rare and serious
diseases, including infectious and ocular diseases.

Isis will receive an upfront payment of $35 million under the deal which covers
up to six programs. In addition to the upfront payment, the company also stands
to receive up to $20 million in milestone payments for each program up to the
phase II proof-of-concept (PoC) stage.

On completion of PoC studies, Glaxo has the option to license the compounds and
take over the development and commercialization of the compounds. If all six
programs are successful and commercialized to pre-determined sales targets, Isis
could receive almost $1.5 billion in license fees and milestone payments.

Isis is also eligible to receive tiered double-digit royalties on sales of
products that are commercialized.

This deal is a major boost for Isis. It not only validates the company`s
antisense technology, it also provides the company with funds in the form of
upfront, milestone and other payments. Meanwhile, this deal will allow Glaxo to
gain access to Isis` antisense technology which has the potential to be used for
the development of several therapeutic treatments.

We are big fans of antisense technology which is the main area of focus at Isis.
We believe that antisense technology represents an exciting and potentially
revolutionary platform for developing therapeutic candidates to treat a wide
margin of diseases.

Isis has several proprietary compounds in clinical development as well as
partnered programs with large pharmaceutical companies such as Bristol-Myers
(NYSE: BMY), Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE). We currently have a
Neutral recommendation on the company.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros
newsletter: http://at.zacks.com/?id=5514.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis
to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks.
Our analysts are organized by industry which gives them keen insights to
developments that affect company profits and stock performance. Recommendations
and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest
analysis from Zacks Equity Research. Subscribe to this free newsletter today:
http://at.zacks.com/?id=5516

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in
1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns
in stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking system;
the Zacks Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of Profitable
ideas GUARANTEED to be worth your time! Register for your free subscription to
Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should
always research companies and securities before making any investments. Nothing
herein should be construed as an offer or solicitation to buy or sell any
security.

Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Copyright Business Wire 2010